首页> 外文期刊>Biopharmaceutics and Drug Disposition >Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole.
【24h】

Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole.

机译:与伊曲康唑或氟康唑同时施用去羟肌苷包裹的肠溶珠制剂后,无临床相关药物相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

This open-label, two-way crossover study was undertaken to determine whether the enteric formulation of didanosine influences the pharmacokinetics of itraconazole or fluconazole, two agents frequently used to treat fungal infections that occur with HIV infection, and whose bioavailability may be influenced by changes in gastric pH. Healthy subjects were randomized to Treatment A (200-mg itraconazole or 200-mg fluconazole) or Treatment B (same dose of itraconazole or fluconazole with 400 mg of didanosine as an encapsulated, enteric-coated bead formulation). In the itraconazole study, a lack of interaction was concluded if the 90% confidence interval (CI) of the ratio of the geometric means of log-transformed C(max) and AUC(0-T) values of itraconazole and hydroxyitraconazole, the active metabolite of itraconazole, were contained entirely between 0.75 and 1.33. In the fluconazole study, the equivalence interval for C(max) and AUC(0-T) was 0.80-1.25. The data showed that for itraconazole the point estimateand 90% CI of the ratios of C(max) and AUC(0-T) values were 0.98 (0.79, 1.20) and 0.88 (0.71, 1.09), respectively; for hydroxyitraconazole the respective values were 0.91 (0.76, 1.08) and 0.85 (0.68, 1.06). In the fluconazole study, the point estimate and 90% CI of the ratios of C(max) and AUC(0-T) values were 0.98 (0.93, 1.03) and 1.01 (0.99, 1.03), respectively. The T(max) for itraconazole, hydroxyitraconazole, and fluconazole were similar between treatments. Both studies indicated a lack of clinically significant interactions of the didanosine formulation with itraconazole or fluconazole. These results showed that the encapsulated, enteric-coated bead formulation of didanosine can be concomitantly administered with drugs, such as the azole antifungal agents, whose bioavailability may be influenced by interaction with antacids. Copyright 2002 John Wiley & Sons, Ltd.
机译:这项开放式,双向的交叉研究旨在确定二羟肌苷的肠溶制剂是否会影响伊曲康唑或氟康唑的药代动力学,伊曲康唑或氟康唑是两种常用于治疗HIV感染引起的真菌感染的药物,其生物利​​用度可能受到变化的影响在胃酸碱度。健康受试者被随机分配至治疗A(200 mg伊曲康唑或200 mg氟康唑)或治疗B(相同剂量的伊曲康唑或氟康唑与400 mg地那黄碱的包封,肠溶衣珠制剂)。在伊曲康唑研究中,如果对数活性的伊曲康唑和羟基依他康唑的对数转换C(max)和AUC(0-T)值的几何平均值之比的90%置信区间(CI),则认为缺乏相互作用伊曲康唑的代谢产物完全在0.75和1.33之间。在氟康唑研究中,C(max)和AUC(0-T)的当量间隔为0.80-1.25。数据显示,对于伊曲康唑,C(max)和AUC(0-T)值之比的点估计和90%CI分别为0.98(0.79,1.20)和0.88(0.71,1.09);对于羟基依他康唑,各自的值为0.91(0.76,1.08)和0.85(0.68,1.06)。在氟康唑研究中,C(max)和AUC(0-T)值之比的点估计和90%CI分别为0.98(0.93,1.03)和1.01(0.99,1.03)。治疗之间伊曲康唑,羟基伊曲康唑和氟康唑的T(max)相似。两项研究均表明,去羟肌苷制剂与伊曲康唑或氟康唑之间缺乏临床上显着的相互作用。这些结果表明,去羟肌苷的包囊的,肠溶的珠制剂可以与诸如唑类抗真菌剂的药物同时给药,其生物利​​用度可能会受到与抗酸剂相互作用的影响。版权所有2002 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号